Wondering what’s driving the momentum behind BeOne’s solid tumor pipeline at #ASCO26? Hear from Dr. Mark Lanasa, Chief Medical Officer, Solid Tumors, as he shares his perspective on our pipeline spanning breast and gynecologic, lung, and gastrointestinal cancers, and what this progress could mean for patients. Learn more about our presence at ASCO here: https://lnkd.in/gHmgk8NZ #FromFloorToFeed #TeamBeOne
BeOne Medicines
Fabrication de produits pharmaceutiques
Cambridge, Massachusetts 250 352 abonnés
Cancer has no borders. Neither do we.
À propos
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram. We all share the responsibility to report adverse events observed with our products so that they may be investigated, actioned, and communicated accordingly. To report an adverse event or side effect, please talk to your healthcare provider and contact us here: https://beonemedicines.com/contact-us/report-adverse-event/.
- Site web
-
www.beonemedicines.com
Lien externe pour BeOne Medicines
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- + de 10 000 employés
- Siège social
- Cambridge, Massachusetts
- Type
- Société cotée en bourse
- Fondée en
- 2010
- Domaines
- oncology, hematology, cancer treatment, solid tumor et targeted therapy
Lieux
Employés chez BeOne Medicines
Nouvelles
-
Chronic lymphocytic leukemia (CLL) progress has been years in the making. Where options were once limited, long-term data now shows a shift from chemotherapy to targeted therapies, and toward more durable disease control. In USA TODAY, we share our perspective on where the future is heading, and how long-term data is raising the bar for what patients and clinicians can expect. At BeOne, we’re building on strong foundations to push boundaries and help transform lives. Because together, we are how the world stops cancer. Learn more: https://lnkd.in/gE36d6Y4 #BeOneInnovator #BeOneAgainstCancer #ASCO26
The Path to a CLL Cure Begins With a Strong Foundation
-
#News for #Investors and #Media: Long-term leadership in CLL is built on durability, consistency, and confidence in first-line treatment decisions. At #ASCO26, we’re unveiling 78-month data from the Phase 3 study of our BTK inhibitor, reinforcing its foundational role in CLL and redefining possibilities for patients. To learn more, read our latest press release: https://lnkd.in/gvHUuDr4 #CancerResearch #BeOneInnovator
-
-
1 day to go. #ASCO26 kicks off tomorrow, and we’re ready to be immersed in the conversation. With 24 abstracts across hematology and solid tumors, we’ll be sharing new data, connecting with experts, and making bold strides in improving cancer care for patients. If you’re in Chicago, come visit us at Booth 27017. Learn more at: https://lnkd.in/gHmgk8NZ #BeOneAtASCO
-
#News for #Investors and #Media: Newly published data in The New England Journal of Medicine highlight the results of our Phase 3 clinical trial in the first-line treatment of HER2+ gastroesophageal adenocarcinoma, which includes cancers of the stomach, esophagus, and gastroesophageal junction. The trial is evaluating a combination regimen that includes our PD-1 inhibitor with a novel HER2-targeted bispecific antibody and chemotherapy. The publication of the full data in NEJM marks an important moment in the study of this persistently challenging disease area. Learn more: https://lnkd.in/gzsVZwX3 #ASCO26 #BeOneInnovator
-
-
CLL Society recently highlighted data from our early-stage clinical trial evaluating the safety and efficacy of our BTK degrader in patients with Richter transformation, a rare, hard-to-treat aggressive complication of CLL / SLL. Learn more about this important data and what it means for high-risk patients here: https://lnkd.in/g-GQSKJ9 #CLL #SLL #BeOneAgainstCancer
-
-
#News for #Investors and #Media: Congress season is here, and we have an exciting few weeks ahead of us. At #ASCO26 and #EHA26, we’re mapping the future of care in B-cell malignancies, with data from three foundational assets. We’re also showcasing an accelerating solid tumor portfolio with innovative therapies across breast/gynecological, lung and gastrointestinal cancers. Across both congresses, our data reflect the depth of our science, the breadth of our pipeline, and our momentum in redefining leadership in oncology. Stay tuned for more. Explore the data here: https://lnkd.in/g-wfGKNd #BeOneInnovator
-
Today we’re launching One Save Changes Everything – a movement rooted in simple truth: advancement in cancer care doesn’t come from one breakthrough moment; it’s built through countless acts of courage, care, and discovery. With former US Men’s National Team goalkeeper, Tim Howard, we’re spotlighting the power of those moments and how together, we are how the world stops cancer – one patient at a time, one save at a time. Learn more: https://bit.ly/49UrgJV
-
For patients with relapsed or refractory mantle cell lymphoma, options are limited and outcomes can be challenging. That reality drives our innovation at BeOne. Our Chief Medical Officer Amit Agarwal, M.D., Ph.D., shares how our BCL2 inhibitor – the first and only in its class FDA-approved in this setting – represents an important step forward for patients who need new options. Find out more: https://lnkd.in/gAEUh6Qe #BeOneInnovator #TeamBeOne
Redefining what's possible in R/R MCL
-
#News for #Investors and #Media: Today, the U.S. FDA granted accelerated approval for our foundational BCL2 inhibitor for adults with relapsed or refractory mantle cell lymphoma (#MCL). MCL is a rare and often aggressive B-cell malignancy, where treatment options remain limited in the relapsed/refractory setting. This marks the first FDA approved BCL2 inhibitor approved in the U.S. in a decade and the only one in R/R MCL. This milestone reflects our commitment to developing foundational medicines for people living with B-cell malignancies. Read the full announcement: https://lnkd.in/gAEUh6Qe #Oncology #MCL #Hematology
-